Comparison of the Use of Carvedilol Versus Nebivolol in the Treatment of Acute Decompensation in the Patient with Chronic Heart Failure: Evaluation of Clinical Variables

Francisco Jose Sánchez Rivas; Jorge Luis García; Gabriela Guanay; José Hipolito Donis Hernandez

doi:doi:10.11648/j.ajim.20231103.14

| Peer-Reviewed

Comparison of the Use of Carvedilol Versus Nebivolol in the Treatment of Acute Decompensation in the Patient with Chronic Heart Failure: Evaluation of Clinical Variables

Francisco Jose Sánchez Rivas, Jorge Luis García, Gabriela Guanay, José Hipolito Donis Hernandez

Published in American Journal of Internal Medicine (Volume 11, Issue 3)

Received: 9 December 2022 Accepted: 17 January 2023 Published: 31 May 2023

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Previous trials demonstrated the safety of using beta-blockers in the acute decompensation of heart failure; it is unknown whether the use of nebivolol translates into an improvement in clinical parameters at 96 hours, compared to the use of carvedilol in a similar study group. Objectives: To compare the effect of 2 treatment strategies, where the difference is made by the type of beta-blocker, in patients with acutely decompensated chronic heart failure. Methods: A single-center, prospective, experimental, randomized, double-blind clinical trial was carried out, 22 patients with LVEF ≤ 40% were randomly assigned to receive carvedilol or nebivolol with daily dose increase, clinical variables were measured for 96 hours. Results: The carvedilol group reached a maximum dose of 33.3 ± 10 mg and nebivolol 9.37 ± 1.25 mg, with both treatment strategies compensation was achieved in more than 50% of the patients in both groups, without statistically significant differences for the majority of patients. clinical variables, except for greater weight loss in the carvedilol group, reaching an absolute reduction of 5.62 kg (95% CI 3.22-8.02 kg) versus nebivolol with 2.54 kg (95% CI 0. 14-4.94 kg) at 96 hours of follow-up (p 0.001) Conclusions: In patients with acutely decompensated chronic heart failure and reduced LVEF, the use of beta-blockers is safe and well tolerated, guarantees clinical improvement and rapid compensation, with doses diuretic drops. The group with carvedilol showed greater weight reduction, compared to the nebivolol group in the study population.

Published in	American Journal of Internal Medicine (Volume 11, Issue 3)
DOI	10.11648/j.ajim.20231103.14
Page(s)	48-54
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2023. Published by Science Publishing Group

Keywords

Beta-Blockers, Diuretics, Acutely Decompensated Heart Failure

References

[1]	Mosterd A, Hoes A. Clinical epidemiology of heart failure. Heart. 2007; 93: 1137–46.
[2]	Redfield M, Jacobsen S, Burnett J, Mahoney D, Bailey K, Rodeheffer R. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003; 289: 194–202.
[3]	Mann D. Mechanisms and models in heart failure. The Biomechanical model and beyond. Circulation. 2005; 111: 2837; 2848.
[4]	Georghiade M, pang P. Acute heart failure syndromes. J Am Coll Cardiol. 2009 53: 577.
[5]	Grupo de Trabajo de la Sociedad Europea de Cardiología (ESC). Diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. European Heart Journal (2021) 00, 1-128.
[6]	Maddox T, Chair J, Jannuzzi J, Vice Ch, Larry A, Khadijah B, et al. Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction JACC 2021 VOL. 77, NO. 6, 772-810.
[7]	Packer M. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation. 2002; 106: 2194–9.
[8]	Flather M, Shibata M, Coats A, Van Veldhuisen D, Parkhomenko A, Borbola J, et al. SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005; 26: 215–25.
[9]	Colmenares H, et al. Estrategias para el tratamiento de la descompensación aguda del paciente con insuficiencia cardíaca crónica (Ensayo ETICA): efecto sobre los niveles plasmáticos de Norepinefrina, índices ecocardiográficos de función diastólica ventricular izquierda y sobrevida Universidad de Los Andes-Facultad de Medicina-Postgrado en Cardiología. 2005. p. 71 Venezuela Disponible en: http://bdigital.ula.ve/RediCiencia/busquedas/DocumentoRedi.jsp?file=35810&type=ArchivoDocumento&vie=pdf&docu=28754&col=5
[10]	Ekman I, Cleland J, Swedberg K, Charlesworth A, Metra M, PooleW. symptoms in patients with heart failure are prognostic predictors: insights from COMET, journal of cardiac failure 2005; 11, 4.
[11]	Lechat P, Hulot J, Escolano S, Mallet A, Leizorovicz A, Werhlen M, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation 2001; 103: 1428–1433.
[12]	Takeshi K, Justin L. Grodin R, Mentz A, Hernandez J, Metra M, et al. Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND HF trial European Journal of Heart Failure (2016) 1-9.
[13]	Finlay A. McAlister N, MMath J, Ezekowitz A, et al. Meta-analysis: Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure. Annals of Internal Medicine 2009; 150: 784-794.
[14]	Cullington D, Goode K, Clark A, John G. Cleland Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target? European Journal of Heart Failure (2012) 14, 737–747.
[15]	Nikolaidis L, Poornima I, Parikh P, Magovern M, ShenY, Shannon R. The effects of combined versus selective adrenergic blockade on left ventricular and systemic hemodynamics, myocardial substrate preference and regional perfusion in conscious dogs with dilated cardiomyopathy. J Am Coll Cardiol 2006; 47: 1871–81.
[16]	Dibona G. TheWalter B. Canon Memorial Award Lecture. Physiology in perspective: the wisdom of the body. Neural Control of the kidney. Am J Physiol Regul Integr Comp Physiol 2005; 289: R633–41.
[17]	Gómez, J. Estrategias para el manejo farmacológico de la descompensación aguda del paciente con insuficiencia cardíaca crónica (Ética III): efectos sobre variables clínicas, osmolaridad urinaria y niveles urinarios de sodio Universidad de Los Andes-Facultad de Medicina-Postgrado en Cardiología. 2011. p. 52 Disponible en: http://bdigital.ula.ve/RediCiencia/busquedas/DocumentoRedi.jsp?file=36129&type=ArchivoDocumento&view=pdf&docu=29055&col=5
[18]	Sliwa, K. Impact of the initiation carvedilol before angiotensin converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. JACC. 2004; 44; 1525-1830.
[19]	Kociol, R. McNulty, S. Hernandez, A. Markers of Decongestion, Dyspnea Relief, and Clinical Outcomes Among Patients Hospitalized with Acute Heart Failure. Circ Heart Fail. 2013; 6: 240-245.
[20]	Anuradha, L. McNulty, S. Mentz, R. et al. Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure. Circ Heart Fail. 2015; 8: 741-748.
[21]	Mehta, R. Rogers, J. Hasselblad, V. Tasissa, Y. Binanay, C. Califf, R. et al. Association of Weight Change With Subsequent Outcomes in Patients Hospitalized With Acute Decompensated Heart Failure Am J Cardiol 2009; 103: 76–81.
[22]	Tamak Y, Yaku H, Morimoto T, Inuzuka Y, Ozasa N, Yamamoto E, In-Hospital Mortality With Beta-Blocker Use at Admission in Patients With Acute Decompensated Heart Failure J Am Heart Assoc. 2021; 10: e020012.
[23]	Sánchez, F. Donis, J. Mazzei C. González, M. Dávila, D. Carvedilol in Patients with Acutely Decompensated Systolic Heart Failure: Effects on Survival. AJIM 2021; 9 (4): 186-193.

Cite This Article

Plain Text BibTeX RIS

APA Style

Francisco Jose Sánchez Rivas, Jorge Luis García, Gabriela Guanay, José Hipolito Donis Hernandez. (2023). Comparison of the Use of Carvedilol Versus Nebivolol in the Treatment of Acute Decompensation in the Patient with Chronic Heart Failure: Evaluation of Clinical Variables. American Journal of Internal Medicine, 11(3), 48-54. https://doi.org/10.11648/j.ajim.20231103.14

Copy | Download

ACS Style

Francisco Jose Sánchez Rivas; Jorge Luis García; Gabriela Guanay; José Hipolito Donis Hernandez. Comparison of the Use of Carvedilol Versus Nebivolol in the Treatment of Acute Decompensation in the Patient with Chronic Heart Failure: Evaluation of Clinical Variables. Am. J. Intern. Med. 2023, 11(3), 48-54. doi: 10.11648/j.ajim.20231103.14

Copy | Download

AMA Style

Francisco Jose Sánchez Rivas, Jorge Luis García, Gabriela Guanay, José Hipolito Donis Hernandez. Comparison of the Use of Carvedilol Versus Nebivolol in the Treatment of Acute Decompensation in the Patient with Chronic Heart Failure: Evaluation of Clinical Variables. Am J Intern Med. 2023;11(3):48-54. doi: 10.11648/j.ajim.20231103.14

Copy | Download

@article{10.11648/j.ajim.20231103.14,
  author = {Francisco Jose Sánchez Rivas and Jorge Luis García and Gabriela Guanay and José Hipolito Donis Hernandez},
  title = {Comparison of the Use of Carvedilol Versus Nebivolol in the Treatment of Acute Decompensation in the Patient with Chronic Heart Failure: Evaluation of Clinical Variables},
  journal = {American Journal of Internal Medicine},
  volume = {11},
  number = {3},
  pages = {48-54},
  doi = {10.11648/j.ajim.20231103.14},
  url = {https://doi.org/10.11648/j.ajim.20231103.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20231103.14},
  abstract = {Previous trials demonstrated the safety of using beta-blockers in the acute decompensation of heart failure; it is unknown whether the use of nebivolol translates into an improvement in clinical parameters at 96 hours, compared to the use of carvedilol in a similar study group. Objectives: To compare the effect of 2 treatment strategies, where the difference is made by the type of beta-blocker, in patients with acutely decompensated chronic heart failure. Methods: A single-center, prospective, experimental, randomized, double-blind clinical trial was carried out, 22 patients with LVEF ≤ 40% were randomly assigned to receive carvedilol or nebivolol with daily dose increase, clinical variables were measured for 96 hours. Results: The carvedilol group reached a maximum dose of 33.3 ± 10 mg and nebivolol 9.37 ± 1.25 mg, with both treatment strategies compensation was achieved in more than 50% of the patients in both groups, without statistically significant differences for the majority of patients. clinical variables, except for greater weight loss in the carvedilol group, reaching an absolute reduction of 5.62 kg (95% CI 3.22-8.02 kg) versus nebivolol with 2.54 kg (95% CI 0. 14-4.94 kg) at 96 hours of follow-up (p 0.001) Conclusions: In patients with acutely decompensated chronic heart failure and reduced LVEF, the use of beta-blockers is safe and well tolerated, guarantees clinical improvement and rapid compensation, with doses diuretic drops. The group with carvedilol showed greater weight reduction, compared to the nebivolol group in the study population.},
 year = {2023}
}

Copy | Download

TY  - JOUR
T1  - Comparison of the Use of Carvedilol Versus Nebivolol in the Treatment of Acute Decompensation in the Patient with Chronic Heart Failure: Evaluation of Clinical Variables
AU  - Francisco Jose Sánchez Rivas
AU  - Jorge Luis García
AU  - Gabriela Guanay
AU  - José Hipolito Donis Hernandez
Y1  - 2023/05/31
PY  - 2023
N1  - https://doi.org/10.11648/j.ajim.20231103.14
DO  - 10.11648/j.ajim.20231103.14
T2  - American Journal of Internal Medicine
JF  - American Journal of Internal Medicine
JO  - American Journal of Internal Medicine
SP  - 48
EP  - 54
PB  - Science Publishing Group
SN  - 2330-4324
UR  - https://doi.org/10.11648/j.ajim.20231103.14
AB  - Previous trials demonstrated the safety of using beta-blockers in the acute decompensation of heart failure; it is unknown whether the use of nebivolol translates into an improvement in clinical parameters at 96 hours, compared to the use of carvedilol in a similar study group. Objectives: To compare the effect of 2 treatment strategies, where the difference is made by the type of beta-blocker, in patients with acutely decompensated chronic heart failure. Methods: A single-center, prospective, experimental, randomized, double-blind clinical trial was carried out, 22 patients with LVEF ≤ 40% were randomly assigned to receive carvedilol or nebivolol with daily dose increase, clinical variables were measured for 96 hours. Results: The carvedilol group reached a maximum dose of 33.3 ± 10 mg and nebivolol 9.37 ± 1.25 mg, with both treatment strategies compensation was achieved in more than 50% of the patients in both groups, without statistically significant differences for the majority of patients. clinical variables, except for greater weight loss in the carvedilol group, reaching an absolute reduction of 5.62 kg (95% CI 3.22-8.02 kg) versus nebivolol with 2.54 kg (95% CI 0. 14-4.94 kg) at 96 hours of follow-up (p 0.001) Conclusions: In patients with acutely decompensated chronic heart failure and reduced LVEF, the use of beta-blockers is safe and well tolerated, guarantees clinical improvement and rapid compensation, with doses diuretic drops. The group with carvedilol showed greater weight reduction, compared to the nebivolol group in the study population.
VL  - 11
IS  - 3
ER  -

Copy | Download

Author Information

Francisco Jose Sánchez Rivas

Department of Medicine, Cardiovascular Investigation Institute, The Andes University Hospital, The Andes University, Mérida, Venezuela
Jorge Luis García

Department of Medicine, Cardiovascular Investigation Institute, The Andes University Hospital, The Andes University, Mérida, Venezuela
Gabriela Guanay

Department of Medicine, Cardiovascular Investigation Institute, The Andes University Hospital, The Andes University, Mérida, Venezuela
José Hipolito Donis Hernandez

Cardiovascular Institute, The Andes University, Mérida, Venezuela

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Francisco Jose Sánchez Rivas, Jorge Luis García, Gabriela Guanay, José Hipolito Donis Hernandez. (2023). Comparison of the Use of Carvedilol Versus Nebivolol in the Treatment of Acute Decompensation in the Patient with Chronic Heart Failure: Evaluation of Clinical Variables. American Journal of Internal Medicine, 11(3), 48-54. https://doi.org/10.11648/j.ajim.20231103.14

Copy | Download

ACS Style

Francisco Jose Sánchez Rivas; Jorge Luis García; Gabriela Guanay; José Hipolito Donis Hernandez. Comparison of the Use of Carvedilol Versus Nebivolol in the Treatment of Acute Decompensation in the Patient with Chronic Heart Failure: Evaluation of Clinical Variables. Am. J. Intern. Med. 2023, 11(3), 48-54. doi: 10.11648/j.ajim.20231103.14

Copy | Download

AMA Style

Francisco Jose Sánchez Rivas, Jorge Luis García, Gabriela Guanay, José Hipolito Donis Hernandez. Comparison of the Use of Carvedilol Versus Nebivolol in the Treatment of Acute Decompensation in the Patient with Chronic Heart Failure: Evaluation of Clinical Variables. Am J Intern Med. 2023;11(3):48-54. doi: 10.11648/j.ajim.20231103.14

Copy | Download

@article{10.11648/j.ajim.20231103.14,
  author = {Francisco Jose Sánchez Rivas and Jorge Luis García and Gabriela Guanay and José Hipolito Donis Hernandez},
  title = {Comparison of the Use of Carvedilol Versus Nebivolol in the Treatment of Acute Decompensation in the Patient with Chronic Heart Failure: Evaluation of Clinical Variables},
  journal = {American Journal of Internal Medicine},
  volume = {11},
  number = {3},
  pages = {48-54},
  doi = {10.11648/j.ajim.20231103.14},
  url = {https://doi.org/10.11648/j.ajim.20231103.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20231103.14},
  abstract = {Previous trials demonstrated the safety of using beta-blockers in the acute decompensation of heart failure; it is unknown whether the use of nebivolol translates into an improvement in clinical parameters at 96 hours, compared to the use of carvedilol in a similar study group. Objectives: To compare the effect of 2 treatment strategies, where the difference is made by the type of beta-blocker, in patients with acutely decompensated chronic heart failure. Methods: A single-center, prospective, experimental, randomized, double-blind clinical trial was carried out, 22 patients with LVEF ≤ 40% were randomly assigned to receive carvedilol or nebivolol with daily dose increase, clinical variables were measured for 96 hours. Results: The carvedilol group reached a maximum dose of 33.3 ± 10 mg and nebivolol 9.37 ± 1.25 mg, with both treatment strategies compensation was achieved in more than 50% of the patients in both groups, without statistically significant differences for the majority of patients. clinical variables, except for greater weight loss in the carvedilol group, reaching an absolute reduction of 5.62 kg (95% CI 3.22-8.02 kg) versus nebivolol with 2.54 kg (95% CI 0. 14-4.94 kg) at 96 hours of follow-up (p 0.001) Conclusions: In patients with acutely decompensated chronic heart failure and reduced LVEF, the use of beta-blockers is safe and well tolerated, guarantees clinical improvement and rapid compensation, with doses diuretic drops. The group with carvedilol showed greater weight reduction, compared to the nebivolol group in the study population.},
 year = {2023}
}

Copy | Download

TY  - JOUR
T1  - Comparison of the Use of Carvedilol Versus Nebivolol in the Treatment of Acute Decompensation in the Patient with Chronic Heart Failure: Evaluation of Clinical Variables
AU  - Francisco Jose Sánchez Rivas
AU  - Jorge Luis García
AU  - Gabriela Guanay
AU  - José Hipolito Donis Hernandez
Y1  - 2023/05/31
PY  - 2023
N1  - https://doi.org/10.11648/j.ajim.20231103.14
DO  - 10.11648/j.ajim.20231103.14
T2  - American Journal of Internal Medicine
JF  - American Journal of Internal Medicine
JO  - American Journal of Internal Medicine
SP  - 48
EP  - 54
PB  - Science Publishing Group
SN  - 2330-4324
UR  - https://doi.org/10.11648/j.ajim.20231103.14
AB  - Previous trials demonstrated the safety of using beta-blockers in the acute decompensation of heart failure; it is unknown whether the use of nebivolol translates into an improvement in clinical parameters at 96 hours, compared to the use of carvedilol in a similar study group. Objectives: To compare the effect of 2 treatment strategies, where the difference is made by the type of beta-blocker, in patients with acutely decompensated chronic heart failure. Methods: A single-center, prospective, experimental, randomized, double-blind clinical trial was carried out, 22 patients with LVEF ≤ 40% were randomly assigned to receive carvedilol or nebivolol with daily dose increase, clinical variables were measured for 96 hours. Results: The carvedilol group reached a maximum dose of 33.3 ± 10 mg and nebivolol 9.37 ± 1.25 mg, with both treatment strategies compensation was achieved in more than 50% of the patients in both groups, without statistically significant differences for the majority of patients. clinical variables, except for greater weight loss in the carvedilol group, reaching an absolute reduction of 5.62 kg (95% CI 3.22-8.02 kg) versus nebivolol with 2.54 kg (95% CI 0. 14-4.94 kg) at 96 hours of follow-up (p 0.001) Conclusions: In patients with acutely decompensated chronic heart failure and reduced LVEF, the use of beta-blockers is safe and well tolerated, guarantees clinical improvement and rapid compensation, with doses diuretic drops. The group with carvedilol showed greater weight reduction, compared to the nebivolol group in the study population.
VL  - 11
IS  - 3
ER  -

Copy | Download